AZ/MedImmune's FluMist gets big boost with new indication
MedImmune announced that the FDA has approved the use of its FluMist in children 2-5 years old, an indication that significantly expands the market for the nasal vaccine.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.